Hct Beta (Hydrochlorothiazide)

Hct Beta is indicated for the oral treatment of two primary conditions in clinical practice.

• Hypertension (high blood pressure) management, either as monotherapy or in combination with other antihypertensives.
• Edema associated with congestive heart failure, hepatic cirrhosis, or renal disease.
• Adjunct therapy for reducing fluid overload in patients undergoing dialysis.
• Prevention of calcium‑containing kidney stones by promoting calcium excretion.
• Short‑term control of blood pressure spikes during peri‑operative periods.

The safety profile of Hct Beta reflects the pharmacology of hydrochlorothiazide, with most patients experiencing mild, reversible reactions, while rare events may require medical attention.

Common

• Increased frequency of urination, especially during the first weeks of therapy.
• Low blood potassium (hypokalemia) leading to muscle cramps or weakness.
• Slight rise in blood glucose levels, which may affect diabetic monitoring.
• Mild dizziness or light‑headedness due to reduced blood volume.

Serious

• Severe electrolyte disturbances such as hyponatremia or hyperuricemia.
• Acute allergic reactions, including rash, itching, or swelling of the face and throat.

Before initiating Hct Beta, clinicians should evaluate patient history and laboratory values to minimize risks and ensure appropriate use.

• Assess renal function; avoid use in patients with severe impairment.
• Monitor serum electrolytes, especially potassium and sodium, during treatment.
• Use caution in patients with diabetes, gout, or a history of hyperlipidaemia.
• Evaluate liver function when edema is related to hepatic disease.
• Consider pregnancy status; hydrochlorothiazide is classified as category B.
• Review concomitant use of other diuretics or antihypertensives to prevent excessive volume loss.

Hydrochlorothiazide can alter the pharmacokinetics or pharmacodynamics of several medicines, making awareness of drug interactions essential for safe therapy.

Avoid

• Concurrent use with lithium, which may increase lithium toxicity.
• Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) that can reduce diuretic efficacy and impair renal function.

Use with caution

• ACE inhibitors or angiotensin receptor blockers, which may enhance potassium loss.
• Antidiabetic agents, as blood glucose may rise and dosage adjustments could be needed.
• Digoxin, because electrolyte shifts can increase the risk of digoxin toxicity.